Table 1. Stage Tis, Ta mRNA Cohort – 189 Patients.
| Characteristic | N (%) |
|---|---|
| Median Age (IQR) | 67 (58-74) |
| Male | 154 (81) |
| High Grade* | 64 (34) |
| CIS+ | 17 (9) |
| EORTC High-Risk Group | 67 (35) |
| Median Follow-up in Years (IQR) | 4.8 (3.4-6.7) |
| Progression to T2 | 21 (11) |
| Deaths | 57 (30) |
2004 World Health Organization grade definitions
** European Organisation for Research and Treatment of Cancer